Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical characteristics of patients

From: Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

 GenderAgeSSc typeDisease durationAutoantibodiesDMARDs
Patient 1F38Limited7ANA, anti-CENP-BMMF, HCQ
Patient 2F62Limited7ANARTX
Patient 3F53Diffuse4ANA, anti-Scl70AZA, HCQ
Patient 4F47Diffuse8ANA, anti-Scl70RTX
Patient 5F38Diffuse2ANA, anti-Scl70AZA
Patient 6F45Diffuse9ANA, anti-CENP-BHCQ
Patient 7F33Diffuse9ANAMMF
Patient 8F51Diffuse5ANA, anti-Scl70MMF
Patient 9F41Diffuse2ANAHCQ
Patient 10F40Diffuse7ANA, anti-Scl70MMF, HCQ
  1. MMF mycophenolate mofetil, HCQ hydroxychloroquine, RTX rituximab, AZA azathioprine